Published in J Am Coll Cardiol on July 07, 2004
Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm (2010) 2.42
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology (2006) 2.26
Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm (2006) 1.86
Post-operative atrial fibrillation: a maze of mechanisms. Europace (2011) 1.12
Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol (2005) 1.05
Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc (2012) 0.99
Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res (2014) 0.97
Atrial fibrillation: challenges and opportunities. Can J Cardiol (2006) 0.87
Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. Methodist Debakey Cardiovasc J (2016) 0.83
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis. Kidney Int (2015) 0.82
Atrial fibrillation and inflammation. World J Cardiol (2010) 0.81
Clinical use of and future perspectives on antiarrhythmic drugs. Eur J Clin Pharmacol (2008) 0.80
Preventive effect of renin-angiotensin system inhibitors on new-onset atrial fibrillation in hypertensive patients: a propensity score matching analysis. J Hum Hypertens (2016) 0.78
Early management of atrial fibrillation: from imaging to drugs to ablation. Nat Rev Cardiol (2010) 0.78
Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice. J Interv Card Electrophysiol (2008) 0.77
Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. Can J Cardiol (2006) 0.77
Impaired heart rate recovery is associated with new-onset atrial fibrillation: a prospective cohort study. BMC Cardiovasc Disord (2009) 0.76
The role of the renin-angiotensin system blocking in the management of atrial fibrillation. J Drug Assess (2012) 0.75
Renin-angiotensin blockade in atrial fibrillation: where are we now? J Hum Hypertens (2017) 0.75
The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: a possible contributing mechanism. J Am Coll Cardiol (2005) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J (2005) 4.06
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
A multimodal analgesia protocol for total knee arthroplasty. A randomized, controlled study. J Bone Joint Surg Am (2006) 2.73
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation (2010) 2.51
Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol (2003) 2.48
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation (2011) 2.36
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation (2008) 2.34
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. J Thorac Cardiovasc Surg (2007) 2.24
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation (2003) 2.16
Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol (2005) 2.14
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol (2002) 2.00
Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf (2005) 1.92
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation (2007) 1.88
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation (2012) 1.81
The Canadian STOP-PAIN project - Part 1: Who are the patients on the waitlists of multidisciplinary pain treatment facilities? Can J Anaesth (2010) 1.80
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol (2011) 1.78
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol (2013) 1.70
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation (2003) 1.69
Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation (2004) 1.64
Absence of association between infectious agents and endothelial function in healthy young men. Circulation (2003) 1.60
Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm (2012) 1.59
Survey on transfusion practices of pediatric intensivists. Pediatr Crit Care Med (2002) 1.55
The Canadian STOP-PAIN project - Part 2: What is the cost of pain for patients on waitlists of multidisciplinary pain treatment facilities? Can J Anaesth (2010) 1.54
Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv (2007) 1.53
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res (2008) 1.51
Effects of anesthetic induction in patients with diastolic dysfunction. Can J Anaesth (2009) 1.50
Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. Circ Arrhythm Electrophysiol (2012) 1.50
Late iatrogenic coronary stenosis after selective intraoperative antegrade myocardial protection for stentless aortic valve replacement. J Thorac Cardiovasc Surg (2006) 1.48
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail (2012) 1.48
Novel therapeutic aspects of percutaneous aortic valve replacement with the 21F CoreValve Revalving System. Catheter Cardiovasc Interv (2007) 1.45
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol (2012) 1.44
Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovasc Res (2011) 1.44
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg (2007) 1.44
Two-year angiographic follow-up of intracoronary Sr90 therapy for restenosis prevention after balloon angioplasty. Circulation (2002) 1.42
Challenge of informing patient decision making: what can we tell patients considering long-term mechanical circulatory support about outcomes, daily life, and end-of-life issues? Circ Cardiovasc Qual Outcomes (2014) 1.41
Incidence of stent under-deployment as a cause of in-stent restenosis in long stents. Int J Cardiovasc Imaging (2004) 1.41
Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study. Circ Arrhythm Electrophysiol (2011) 1.40
Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery. Can J Anaesth (2007) 1.39
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol (2003) 1.39
Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet (2011) 1.38
In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging (2009) 1.37
Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention (2011) 1.35
Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation (2002) 1.31
Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol (2003) 1.29
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension (2007) 1.29
Cardiac masses: an integrative approach using echocardiography and other imaging modalities. Heart (2011) 1.29
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Prevalence of and risk factors for persistent postoperative nonanginal pain after cardiac surgery: a 2-year prospective multicentre study. CMAJ (2014) 1.23
Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol (2007) 1.23
Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol (2003) 1.23
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol (2007) 1.22
Acute coronary syndromes in young patients: presentation, treatment and outcome. Int J Cardiol (2009) 1.21
Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol (2012) 1.20
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol (2008) 1.15
Optimus Primer: A PCR enrichment primer design program for next-generation sequencing of human exonic regions. BMC Res Notes (2010) 1.14
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res (2002) 1.12
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas (2009) 1.10
Relation of myocardial perfusion defects and nonsignificant coronary lesions by angiography with insights from intravascular ultrasound and coronary pressure measurements. Am J Cardiol (2005) 1.10
Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res (2010) 1.09
Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 1.09
Diagnostic accuracy of pocket-size handheld echocardiographs used by cardiologists in the acute care setting. Eur Heart J Cardiovasc Imaging (2012) 1.09
Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation (2005) 1.07